JAC Advance Access published online on April 6, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl143
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine E, Beilinson Campus, Rabin Medical Center, 49100 Petah-Tiqva, Israel
* To whom correspondence should be addressed.
Correspondence
Comment on Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK
Leonard Leibovici 1 *
and
Mical Paul 1
Leonard Leibovici, E-mail: leibovic{at}post.tau.ac.il
This article has no Abstract.
Keywords:
Staphylococcus spp.; antibiotic policy; empirical treatment.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A Howe Don't include trimethoprim BMJ, April 12, 2008; 336(7648): 787 - 787. [Full Text] [PDF] |
||||

